Similar articles

• Targeted therapy in chronic lymphocytic leukemia: past, present, and future.

  Danilov AV. Danilov AV. Clin Ther. 2013 Sep;35(9):1258-70. doi: 10.1016/j.clinthera.2013.08.004. Clin Ther. 2013. PMID: 24054703 Free PMC article. Review.
• B cell receptor inhibition as a target for CLL therapy.

  Jeyakumar D, O'Brien S. Jeyakumar D, et al. Best Pract Res Clin Haematol. 2016 Mar;29(1):2-14. doi: 10.1016/j.beha.2016.08.004. Epub 2016 Aug 11. Best Pract Res Clin Haematol. 2016. PMID: 27742069 Review.
• BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.

  Spaargaren M, de Rooij MF, Kater AP, Eldering E. Spaargaren M, et al. Oncogene. 2015 May 7;34(19):2426-36. doi: 10.1038/onc.2014.181. Epub 2014 Jun 23. Oncogene. 2015. PMID: 24954503 Review.
• The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

  Wiestner A. Wiestner A. Haematologica. 2015 Dec;100(12):1495-507. doi: 10.3324/haematol.2014.119123. Haematologica. 2015. PMID: 26628631 Free PMC article. Review.
• Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.

  Foluso O, Glick A, Stender M, Jaiyesimi I. Foluso O, et al. Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):63-9. doi: 10.1016/j.clml.2015.11.011. Epub 2015 Nov 22. Clin Lymphoma Myeloma Leuk. 2016. PMID: 26775273 Review.